Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems
Abstract Cancer remains the second leading cause of death globally, driving the need for innovative therapies. Among natural compounds, maytansinoids have shown significant promise, contributing to nearly 25% of recently approved anticancer drugs. Despite their potential, early clinical trials faced...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-01-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-01820-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585622078881792 |
|---|---|
| author | Matteo Perra Ines Castangia Matteo Aroffu Federica Fulgheri Rita Abi-Rached Maria Letizia Manca Hernán Cortés María Luisa Del Prado-Audelo Carla Nomura-Contreras Alejandra Romero-Montero Dietrich Büsselberg Gerardo Leyva-Gómez Javad Sharifi-Rad Daniela Calina |
| author_facet | Matteo Perra Ines Castangia Matteo Aroffu Federica Fulgheri Rita Abi-Rached Maria Letizia Manca Hernán Cortés María Luisa Del Prado-Audelo Carla Nomura-Contreras Alejandra Romero-Montero Dietrich Büsselberg Gerardo Leyva-Gómez Javad Sharifi-Rad Daniela Calina |
| author_sort | Matteo Perra |
| collection | DOAJ |
| description | Abstract Cancer remains the second leading cause of death globally, driving the need for innovative therapies. Among natural compounds, maytansinoids have shown significant promise, contributing to nearly 25% of recently approved anticancer drugs. Despite their potential, early clinical trials faced challenges due to severe side effects, prompting advancements in delivery systems such as antibody-maytansinoid conjugates (AMCs). This review highlights the anticancer activity of maytansinoids, with a focus on AMCs designed to target cancer cells specifically. Preclinical and clinical studies show that AMCs, including FDA-approved drugs like Kadcyla and Elahere, effectively inhibit tumor growth while reducing systemic toxicity. Key developments include improved synthesis methods, linker chemistry and payload design. Ongoing research aims to enhance the safety and efficacy of AMCs, integrate nanotechnology for drug delivery, and identify novel therapeutic targets. These advancements hold potential to transform maytansinoid-based cancer treatments in the future. |
| format | Article |
| id | doaj-art-2a093abc90bd4a86bba5e5b4744aa8ca |
| institution | Kabale University |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-2a093abc90bd4a86bba5e5b4744aa8ca2025-01-26T12:39:58ZengSpringerDiscover Oncology2730-60112025-01-0116112410.1007/s12672-025-01820-zMaytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systemsMatteo Perra0Ines Castangia1Matteo Aroffu2Federica Fulgheri3Rita Abi-Rached4Maria Letizia Manca5Hernán Cortés6María Luisa Del Prado-Audelo7Carla Nomura-Contreras8Alejandra Romero-Montero9Dietrich Büsselberg10Gerardo Leyva-Gómez11Javad Sharifi-Rad12Daniela Calina13DISVA-Department of Life and Environmental Sciences, University of CagliariDISVA-Department of Life and Environmental Sciences, University of CagliariDISVA-Department of Life and Environmental Sciences, University of CagliariDISVA-Department of Life and Environmental Sciences, University of CagliariDISVA-Department of Life and Environmental Sciences, University of CagliariDISVA-Department of Life and Environmental Sciences, University of CagliariLaboratorio de Medicina Genómica, Departamento de Genómica, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra IbarraTecnologico de Monterrey, Escuela de Ingeniería y CienciasTecnologico de Monterrey, Escuela de Ingeniería y CienciasDepartamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de MéxicoWeill Cornell Medicine-Qatar, Education City, Qatar FoundationDepartamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de MéxicoUniversidad Espíritu SantoDepartment of Clinical Pharmacy, University of Medicine and Pharmacy of CraiovaAbstract Cancer remains the second leading cause of death globally, driving the need for innovative therapies. Among natural compounds, maytansinoids have shown significant promise, contributing to nearly 25% of recently approved anticancer drugs. Despite their potential, early clinical trials faced challenges due to severe side effects, prompting advancements in delivery systems such as antibody-maytansinoid conjugates (AMCs). This review highlights the anticancer activity of maytansinoids, with a focus on AMCs designed to target cancer cells specifically. Preclinical and clinical studies show that AMCs, including FDA-approved drugs like Kadcyla and Elahere, effectively inhibit tumor growth while reducing systemic toxicity. Key developments include improved synthesis methods, linker chemistry and payload design. Ongoing research aims to enhance the safety and efficacy of AMCs, integrate nanotechnology for drug delivery, and identify novel therapeutic targets. These advancements hold potential to transform maytansinoid-based cancer treatments in the future.https://doi.org/10.1007/s12672-025-01820-zMaytansineMaytansinoid-based therapiesAntibody-maytansinoid conjugatesNatural compoundsAnticancer studiesMicrotubules polymerization inhibitors |
| spellingShingle | Matteo Perra Ines Castangia Matteo Aroffu Federica Fulgheri Rita Abi-Rached Maria Letizia Manca Hernán Cortés María Luisa Del Prado-Audelo Carla Nomura-Contreras Alejandra Romero-Montero Dietrich Büsselberg Gerardo Leyva-Gómez Javad Sharifi-Rad Daniela Calina Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems Discover Oncology Maytansine Maytansinoid-based therapies Antibody-maytansinoid conjugates Natural compounds Anticancer studies Microtubules polymerization inhibitors |
| title | Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems |
| title_full | Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems |
| title_fullStr | Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems |
| title_full_unstemmed | Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems |
| title_short | Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems |
| title_sort | maytansinoids in cancer therapy advancements in antibody drug conjugates and nanotechnology enhanced drug delivery systems |
| topic | Maytansine Maytansinoid-based therapies Antibody-maytansinoid conjugates Natural compounds Anticancer studies Microtubules polymerization inhibitors |
| url | https://doi.org/10.1007/s12672-025-01820-z |
| work_keys_str_mv | AT matteoperra maytansinoidsincancertherapyadvancementsinantibodydrugconjugatesandnanotechnologyenhanceddrugdeliverysystems AT inescastangia maytansinoidsincancertherapyadvancementsinantibodydrugconjugatesandnanotechnologyenhanceddrugdeliverysystems AT matteoaroffu maytansinoidsincancertherapyadvancementsinantibodydrugconjugatesandnanotechnologyenhanceddrugdeliverysystems AT federicafulgheri maytansinoidsincancertherapyadvancementsinantibodydrugconjugatesandnanotechnologyenhanceddrugdeliverysystems AT ritaabirached maytansinoidsincancertherapyadvancementsinantibodydrugconjugatesandnanotechnologyenhanceddrugdeliverysystems AT marialetiziamanca maytansinoidsincancertherapyadvancementsinantibodydrugconjugatesandnanotechnologyenhanceddrugdeliverysystems AT hernancortes maytansinoidsincancertherapyadvancementsinantibodydrugconjugatesandnanotechnologyenhanceddrugdeliverysystems AT marialuisadelpradoaudelo maytansinoidsincancertherapyadvancementsinantibodydrugconjugatesandnanotechnologyenhanceddrugdeliverysystems AT carlanomuracontreras maytansinoidsincancertherapyadvancementsinantibodydrugconjugatesandnanotechnologyenhanceddrugdeliverysystems AT alejandraromeromontero maytansinoidsincancertherapyadvancementsinantibodydrugconjugatesandnanotechnologyenhanceddrugdeliverysystems AT dietrichbusselberg maytansinoidsincancertherapyadvancementsinantibodydrugconjugatesandnanotechnologyenhanceddrugdeliverysystems AT gerardoleyvagomez maytansinoidsincancertherapyadvancementsinantibodydrugconjugatesandnanotechnologyenhanceddrugdeliverysystems AT javadsharifirad maytansinoidsincancertherapyadvancementsinantibodydrugconjugatesandnanotechnologyenhanceddrugdeliverysystems AT danielacalina maytansinoidsincancertherapyadvancementsinantibodydrugconjugatesandnanotechnologyenhanceddrugdeliverysystems |